Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Z Bata-Csorgo"'
Publikováno v:
Bőrgyógyászati és Venerológiai Szemle. 97:71-75
There has been increasing number of reports on the cutaneousmanifestations of COVID-19 patients. The skin involvements in patients with COVID-19 demonstrate various clinical entities. In our article, we summarize these cutaneous manifestations based
Publikováno v:
Journal of Investigative Dermatology. 142:S248
Autor:
B. Gubán, L.B. Flink, R. Bozó, J. Danis, Z. Rázga, B. Koncz, M. Széll, L. Kemény, Z. Bata-Csorgo
Publikováno v:
Journal of Investigative Dermatology. 142:S244
Autor:
A. Ghaffarinia, F. Ayaydin, S. Póliska, B. Bolla, L. Borbára Flink, R. Bozó, K. Szabó, Z. Bata-Csorgo, L. Kemény
Publikováno v:
Journal of Investigative Dermatology. 142:S247
Publikováno v:
Journal of Investigative Dermatology. 142:S248
Autor:
Z. Bata-Csorgo, Evelyn Kelemen, Anikó Göblös, Márta Széll, Éá. dám, Lajos Kemény, Judit Danis, S. Sági
Publikováno v:
Journal of Investigative Dermatology. 141:S184
Autor:
Lajos Kemény, Zoltán Veréb, B.I. Németh, Máté Manczinger, Benjamin Tamás Papp, D.L. Vidacs, Renáta Bozó, Szilárd Póliska, L.B. Flink, Z. Bata-Csorgo, Hilda Polyánka
Publikováno v:
Journal of Investigative Dermatology. 141:S195
Autor:
Lajos Kemény, Eszter Szlávicz, Kornélia Szabó, G. Groma, Franco Pagani, Z. Bata-Csorgo, Márta Széll
Publikováno v:
Molecular and Cellular Biochemistry. 436:189-199
The EDA+ fibronectin splicing variant is overexpressed in psoriatic non-lesional epidermis and sensitizes keratinocytes to mitogenic signals. However, regulation of its abundance is only partially understood. In our recent cDNA microarray experiment,
Autor:
Mazen M. Dimachkie, C. Charles-Schoeman, E. Schiopu, Z. Bata-Csorgo, A. T. Proderm Investigators, Rohit Aggarwal, Zoltán Griger, Sergey Moiseev, Jiří Vencovský, I. Beckmann, T. Levine, E. Clodi, Joachim Schessl, Chester V. Oddis
Publikováno v:
Annals of the Rheumatic Diseases. 80:4.1-5
Background:Dermatomyositis (DM) is a rare chronic systemic autoimmune disease with characteristic skin rash and progressive proximal muscle weakness. Current therapies encompass corticosteroids and other immunosuppressants and intravenous immunoglobu
Autor:
R. Aggarwal, C. Charles-Schoeman, J. Schessl, Z. Bata-Csorgo, M. Dimachkie, Z. Griger, S. Moiseev, C. Oddis, E. Schiopu, J. Vencovsky, I. Beckmann, E. Clodi, T. Levine, ProDERM Investigators
Publikováno v:
Neuromuscular Disorders. 30:S133